TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36036760
Drug: Full-dose anticoagulation
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose anticoagulation
Study: 39217573
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet therapy
Study: 32141136
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (6,000 U/kg) of amylase
Study: 33002971
Drug: Early supplemental
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early supplemental parenteral nutrition
Study: 33002971
Drug: Early total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early total parenteral nutrition
Study: 33002971
Drug: High-dose vasopressors
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vasopressors
Study: 35186243
Drug: Laparoscopic radical
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic radical surgery combined with neoadjuvant chemotherapy
Study: 34266319
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MIC-1, CEA, CA19-9, CA24-2 for CRC diagnosis
Study: 36101543
Drug: Spinal cord
Normalized name: BOS TAURUS SPINAL CORD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal cord stimulation (SCS) therapy
Study: 33186740
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus fulvestrant (500 mg)
Study: 35168030
Drug: Equisetum arvense
Normalized name: Equisetum Arvense
DrugBank: Equisetum arvense top (DB14349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equisetum arvense L. (EA) 900 mg/day
Study: 34078323
Drug: Reduced CNI
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced CNI exposure in combination with everolimus and glucocorticoids
Study: 32728879
Drug: 1 cup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cup of espresso coffee plus 2 cocoa-based products containing coffee, twice per day
Study: 33245709
Drug: Liquid paraffin
Normalized name: Liquid paraffin
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid paraffin (placebo) inhalation
Study: 32812320
Drug: Andecaliximab 800
Normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andecaliximab 800 mg every 2 weeks in combination with gemcitabine and nab-paclitaxel
Study: 33213288
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous alteplase
Study: 34579049
Drug: Test fermented
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test fermented milk containing yogurt and Lacticaseibacillus strains (L. paracasei CNCM I‐1518 and I‐3689, L. rhamnosus CNCM I‐3690) for 28 days
Study: 33914256
Drug: EU-bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: EU-bevacizumab (15 mg/kg)
Study: 34348263
Drug: Additional L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional L-carnitine (1,500 mg/day) and rifaximin (1,200 mg/day)
Study: 37002653
Drug: CBP quadruple
Normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBP quadruple therapy (amoxicillin 1 g twice daily, tetracycline 500 mg three times daily, esomeprazole 20 mg twice daily, CBP 200 mg three times daily)
Study: 37002653
Drug: BPC quadruple
Normalized name: BPC-157
DrugBank: BPC-157 (DB11882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPC quadruple therapy (amoxicillin 1 g twice daily, tetracycline 500 mg three times daily, esomeprazole 20 mg twice daily, BPC 240 mg twice daily)
Study: 33116029
Drug: cream-type denture
Normalized name: ALCOHOL,DENATURED
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream-type denture adhesive
Study: 33116029
Drug: control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: control (saline solution)
Study: 34904623
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine
Study: 34383535
Drug: Group mindfulness-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group mindfulness-based cognitive therapy (MBCT)
Study: 34383535
Drug: Group supportive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group supportive sex education and therapy (STEP)
Study: 35965904
Drug: Intralesional tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional tranexamic acid (TXA) 4 mg/mL
Study: 35965904
Drug: Topical Kligman's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Kligman's therapy
Study: 35397289
Drug: Repeat infusion
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat infusion of autologous bone marrow
Study: 36109141
Drug: Third COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third COVID-19 vaccination with an mRNA vaccine
Study: 35309844
Drug: Danzhi Xiaoyao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danzhi Xiaoyao Powder combined with photodynamic therapy (PDT)
Study: 33894496
Drug: 70 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 Gy daily (QD)
Study: 33894496
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and etoposide chemotherapy with TRT regimens
Study: 33357808
Drug: Aging Treatment
Normalized name: Similas Aging Eye Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aging Treatment Model
Study: 32366124
Drug: Therapy (38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy (38 participants)
Study: 32896022
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Panax quinquefolius
Study: 35368763
Drug: Kleeb Bua
Normalized name: Kleer Plex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kleeb Bua Daeng (KBD) formula, 1,000 mg twice a day for three months
Study: 33034099
Drug: Hydrocortisone 1%
Normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone 1% ointment
Study: 33253210
Drug: Standard antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antifungal treatment with adjunctive dexamethasone
Study: 33253210
Drug: Standard antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antifungal treatment without adjunctive dexamethasone
Study: 32039689
Drug: Fragrance inhalation
Normalized name: Myristica fragrans fruit
DrugBank: Myristica fragrans fruit (DB15544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragrance inhalation of grapefruit essential oil for 10 minutes (study 1)
Study: 32039689
Drug: Fragrance inhalation
Normalized name: Myristica fragrans fruit
DrugBank: Myristica fragrans fruit (DB15544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragrance inhalation of grapefruit essential oil for 10 minutes (study 2)
Study: 32039689
Drug: Fragrance inhalation
Normalized name: Myristica fragrans fruit
DrugBank: Myristica fragrans fruit (DB15544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragrance inhalation of grapefruit essential oil (last 5 minutes of inhalation)
Study: 32608134
Drug: ARE0 (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARE0 (0 g kg-1)
Study: 32608134
Drug: ARE20 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARE20 (20 g kg-1)
Study: 32608134
Drug: ARE50 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARE50 (50 g kg-1)
Study: 32608134
Drug: ARE80 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARE80 (80 g kg-1)
Study: 33060555
Drug: Regular scheduled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular scheduled ibuprofen (10 mg/kg per dose, maximum 600 mg every 6 hours)
Study: 33060555
Drug: Pro re
Normalized name: Blistex Pro Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro re nata (PRN) ibuprofen
Study: 33060555
Drug: Regular scheduled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular scheduled ibuprofen
Study: 34456194
Drug: ACTH administration
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH administration (3 times daily for 7 days)
Study: 32991232
Drug: Cardiac rehabilitation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac rehabilitation group (CR) with standard medical treatments and exercise-based cardiac rehabilitation
Study: 32991232
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with standard medical treatments without exercise
Study: 33129628
Drug: Dyadic intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dyadic intervention to improve communication (4 weekly sessions)
Study: 37419144
Drug: Amikacin liposome
Normalized name: AMIKACIN LIPOSOME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin liposome inhalation suspension (ALIS)
Study: 37258803
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg) + Sitagliptin (100 mg) + Metformin (1000 mg) ER
Study: 37258803
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg) + Metformin (1000 mg) SR
Study: 37258803
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg) + Metformin (1000 mg) ER
Study: 37258803
Drug: Dapagliflozin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin + Sitagliptin + Metformin ER
Study: 34235909
Drug: InGaAsP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: InGaAsP and Er,Cr:YSGG laser adjunctive to subgingival debridement
Study: 39642783
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure Therapy (PE)
Study: 36103260
Drug: Levothyroxine 50mcg
Normalized name: LEVOTHYROXINE 50MCG/ML ORAL SOLN UD
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine 50mcg daily
Study: 32931996
Drug: Modified Mindfulness-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Mindfulness-Based Cognitive Therapy (MBCT)
Study: 32425802
Drug: Pimavanserin 34
Normalized name: pimavanserin 34 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimavanserin 34 mg/day
Study: 33993136
Drug: Enhanced oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced oral care (intervention units)
Study: 33993136
Drug: Usual oral
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oral care (control units)
Study: 32325012
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (ciprofloxacin 750 mg every 12 h and metronidazole 250 mg every 8 h the day before surgery)
Study: 32325012
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral antibiotics (control group)
Study: 32325012
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (experimental group)
Study: 32400732
Drug: Traditional massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional massage in addition to routine physical therapy (once daily, five times a week for three months)
Study: 32400732
Drug: Routine physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine physical therapy (once daily, five times a week for three months)
Study: 35728048
Drug: Azacitidine monotherapy
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine monotherapy (n = 227)
Study: 37070436
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 12 weeks)
Study: 32902668
Drug: Submucosal dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Submucosal dexamethasone (8 mg)
Study: 36098362
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus Bifidobacterium animalis subsp. lactis (BB‐12) probiotic (MET-PRO group)
Study: 36098362
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone (MET group)
Study: 33811308
Drug: Sulpiride (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (200 mg)
Study: 36181480
Drug: 100-mg testosterone
Normalized name: testosterone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg testosterone cypionate (weekly intramuscular injections)
Study: 36181480
Drug: Placebo (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (weekly intramuscular injections)
Study: 34452930
Drug: Ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks
Study: 34176722
Drug: CNSA-001 (sepiapterin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNSA-001 (sepiapterin, PTC923) 10 mg/kg BID for 14 days
Study: 35278283
Drug: Dupilumab 200
Normalized name: dupilumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 200 mg administered via autoinjector (AI)
Study: 35278283
Drug: Dupilumab 200
Normalized name: dupilumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 200 mg administered via prefilled syringe with needle shield (PFS-S)
Study: 32363743
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg enalapril and 0.8 mg folic acid
Study: 32363743
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg enalapril alone
Study: 33291649
Drug: 0.6 L/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 L/day of an artificially sweetened soft drink containing acesulfame K (950) and aspartame (951) for 2 weeks
Study: 33291649
Drug: 0.6 L/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 L/day of mineral water for 2 weeks
Study: 33671093
Drug: LEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEA with low protein (LEA-LP; 0.8 g protein·kg BW-1)
Study: 33671093
Drug: LEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEA with high protein (LEA-HP; 1.7 g protein·kg BW-1)
Study: 33671093
Drug: Control (CON;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (CON; 40 kcal·kg FFM-1·day-1, 1.7 g protein·kg BW-1)
Study: 33087055
Drug: Selenium (L‐selenomethionine)
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (L‐selenomethionine) 200 μg/day for 3 months
Study: 33087055
Drug: Control (nothing,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (nothing, in addition to recommended therapy)
Study: 35665800
Drug: Precision prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision prevention materials incorporating melanocortin‐1 receptor genetic risk information
Study: 33872587
Drug: Mepolizumab 100
Normalized name: mepolizumab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 100 mg subcutaneously once every 4 weeks for 52 weeks
Study: 33745228
Drug: Unguided web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided web-based cognitive behavioral therapy (CBT) program for IBS
Study: 34357466
Drug: Pantoprazole 80
Normalized name: pantoprazole 80 MG in 100 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 80 mg with cisplatin
Study: 34357466
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg with cisplatin
Study: 32281641
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy during hospitalization
Study: 32281641
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy after discharge
Study: 35148036
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment protocol
Study: 32466710
Drug: Alcoholic drink
Normalized name: Alcoholic drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcoholic drink (0.4 g/kg)
Study: 37318120
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with 8 mg intravenous ondansetron
Study: 32333793
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2.5 g daily for four months)
Study: 33260552
Drug: Oolong tea
Normalized name: oolong tea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oolong tea (100 mg caffeine, 21.4 mg gallic acid, 97 mg catechins, 125 mg polymerized polyphenol)
Study: 34693501
Drug: Metoclopramide 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.2 mg/kg three times daily, administered 15 min before feeding, up to term.
Study: 36172027
Drug: Idebenone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone (30 mg each time, three times a day)
Study: 35379286
Drug: Intra-arterial vasodilatory
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial vasodilatory therapy (prostaglandin infusion)
Study: 32430540
Drug: Alcohol (male:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (male: 0.55 g/kg, female: 0.45 g/kg)
Study: 32285710
Drug: Water (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (250 mL)
Study: 33565516
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements (ONSs)
Study: 36358943
Drug: Pregnenolone (PREG)
DrugBank: Pregnenolone acetate (DB14626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone (PREG) 500 mg/day
Study: 36358943
Drug: Pregnenolone (PREG)
DrugBank: Pregnenolone acetate (DB14626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone (PREG) 300 mg/day
Study: 33353913
Drug: 31 gauge
Normalized name: lancets 31 gauge MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 31 gauge needle with topical lignocaine‐prilocaine (31GT)
Study: 33353913
Drug: 27 gauge
Normalized name: 1mL 27 gauge, 0.5 inch syringe with needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 27 gauge needle with topical lignocaine‐prilocaine (27GT)
Study: 35796486
Drug: Ketamine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (75 mg) with 1 mg midazolam
Study: 35796486
Drug: Standard Moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Moderate Sedation (SMS) with midazolam and fentanyl (150 mcg fentanyl, 5 mg midazolam)
Study: 34859459
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous selenium supplementation (3000 mcg after anesthesia induction, 1000 mcg upon ICU admission, and 1000 mcg daily in the ICU for a maximum of 14 days)
Study: 32471143
Drug: Serum ANP
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum ANP levels >64.6 pg/mL
Study: 32471143
Drug: Serum NT-proCNP
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum NT-proCNP levels >1.7 pg/mL
Study: 33785406
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) with traumatic memory reactivation
Study: 33785406
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) with non-traumatic memory reactivation
Study: 34398796
Drug: WeChat-supported platform,
Approvals — FDA: no, EMA: no, PMDA: no
Description: WeChat-supported platform, Medication Housekeeper (MediHK) for 4 weeks, including daily pain diaries, ADR forms every 3 days, and Brief Pain Inventory every 15 days.
Study: 34398796
Drug: WeChat-supported platform,
Approvals — FDA: no, EMA: no, PMDA: no
Description: WeChat-supported platform, Medication Housekeeper (MediHK) for 4 weeks.
Study: 35182889
Drug: internet-delivered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered cognitive-behavioral therapy (ICBT) (iSOMA) for 8 weeks
Study: 33599356
Drug: E6011 (12-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011 (12-week multiple ascending dose phase: 2, 5, 10, and 15 mg/kg intravenously every 2 weeks)
Study: 33599356
Drug: E6011 (12-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011 (12-week multiple ascending dose phase)
Study: 33599356
Drug: E6011 (40-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011 (40-week Extension phase at the same dose as MAD phase)
Study: 33248978
Drug: Drug-Eluting Stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Stent (EES)
Study: 33753275
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (open reduction and screw fixation)
Study: 33753275
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (pressure bandage)
Study: 32243100
Drug: Conventional diuretic
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diuretic therapy (n = 26)
Study: 32773594
Drug: Tapentadol extended-release
Normalized name: Tapentadol Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol extended-release (ER) 50 mg × 2
Study: 32773594
Drug: Oxycodone controlled-release
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone controlled-release (CR) 10 mg × 2
Study: 33789722
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BTX) injection into the cricopharyngeal muscle
Study: 33671310
Drug: Grape Seed
Normalized name: grape seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape Seed Extract (GSEe) 300 mg/day for 16 weeks
Study: 37000390
Drug: Semaglutide 1
Normalized name: semaglutide 14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 1 mg
Study: 32440938
Drug: 3% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% prilocaine with 0.03 IU/mL felypressin (Prilo/Fely)
Study: 32745768
Drug: Coffee A
Normalized name: White Glo Coffee and Tea Stain Remover Fluoride Anticavity KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee A (787 mg CGAs/day)